
Reta-Peptide
Finnrick has tested 69 samples from Reta-Peptide across 5 products.
Finnrick Vendor Profile
to
Reta-Peptide
Tracking 5 products
69 total samples tested
Last test 25 Nov 2025
Take Action
Test My Sample
Researcher
Request Full Data Access to the Finnrick database of peptide tests.
Products
| Tests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Product | Rating | Count | Avg | Min | Max | Oldest | Most Recent | |
| Cagrilintide | 3 | 1 Jul 2025 | 4 Sep 2025 | |||||
| GHK-Cu | 13 | 16 Jul 2025 | 25 Nov 2025 | |||||
| Tirzepatide | 16 | 20 Jun 2025 | 25 Nov 2025 | |||||
| BPC-157 | 7 | 16 Jul 2025 | 25 Nov 2025 | |||||
| Retatrutide | 30 | 20 Jun 2025 | 25 Nov 2025 | |||||
Most recent Reta-Peptide tests
Samples are tested in commercial labs
69
tests
5
products
Scores
AVGMINMAX
First
20 Jun 2025
Last
25 Nov 2025
| Quantity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Product | Certificate | Test Score | Label | Tested | Difference | Purity | Batch ID | Container | Tested At | Sent By |
| 25 Nov 2025 | Retatrutide | View | 5mg | 5.370mg | +7.4% | 99.95% | (no batch ID) | No Label / Silver Crimp / Blue Cap | Lab E | Public | |
| 25 Nov 2025 | GHK-Cu | View | 50mg | 51.600mg | +3.2% | 99.93% | (no batch ID) | No Label / Silver Crimp / Blue Cap | Lab E | Public | |
| 25 Nov 2025 | Retatrutide | View | 30mg | 29.800mg | -0.7% | 99.55% | October 8, 2025 | No Label / Silver Crimp / Pink Cap | Lab E | Public | |
| 25 Nov 2025 | Tirzepatide | View | 30mg | 29.500mg | -1.7% | 99.91% | October 8, 2025 | No Label / Silver Crimp / Green Cap | Lab E | Public | |
| 25 Nov 2025 | GHK-Cu | View | 100mg | 112.000mg | +12.0% | 99.64% | (no batch ID) | No Label / Silver Crimp / Blue Cap | Lab E | Public | |
| 25 Nov 2025 | BPC-157 | View | 5mg | 4.110mg | -17.8% | 99.47% | (no batch ID) | No Label / Silver Crimp / Clear Red Cap | Lab E | Public | |
| 18 Nov 2025 | Retatrutide | View | 20mg | ⚠️ Sample does not contain Retatrutide | (no batch ID) | No Label / Silver Crimp / Red Cap | Lab E | Public | |||